HAEMONETICS CORP (HAE)
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Haemonetics Corporation
Trials need funding. See this company's dilution risk and cash position.
- Phase 1Completed
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
SOLX (Investigational), AS-3 (Control)
Blood Donors
NCT02145507Enrollment170StartApr 2014Primary CompletionDec 2014CompletionJan 2015 - ObservationalCompleted
Thromboelastography (TEG) Reference Range Study
-
Coagulation
NCT01357928Enrollment159StartApr 2011Primary CompletionJul 2011CompletionOct 2011 - ObservationalTerminated
RapidTEG MA Validation
-
Coagulation, Platelet Function
NCT01428102Enrollment17StartJul 2011Primary CompletionOct 2012CompletionOct 2012 - ObservationalCompleted
Clinical Evaluation of the OrthoPAT Advance System
OrthoPat Advance
Transmission, Blood, Recipient/Donor
NCT01756976Enrollment84StartDec 2012Primary CompletionAug 2013CompletionAug 2013 - ObservationalCompleted
Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)
-
Red Blood Cell Donation
NCT01764061Enrollment60StartJan 2013Primary CompletionSep 2013CompletionSep 2013 - ObservationalCompleted
Procedure For The Reference Range Study For Absolute MA
-
Transmission, Blood, Recipient/Donor
NCT02110576Enrollment161StartMay 2014Primary CompletionSep 2014CompletionMar 2015 - Not applicableCompleted
Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder
POLFA (Needle Assembly), Kawasumi (Needle Assembly)
Transmission, Blood, Recipient/Donor
NCT02476851Enrollment62StartJun 2015Primary CompletionJul 2015CompletionSep 2015 - ObservationalCompleted
Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System
TEG6s DOAC Cartridge
DOAC Eligible Subjects
NCT02798328Enrollment385StartAug 2016Primary CompletionSep 2017CompletionSep 2017 - Not applicableCompleted
IMPACT (Improving Plasma Collection) Clinical Trial
Updated Plasma Collection Feature, Current Plasma Collection Approach
Apheresis Related Hypotension
NCT04320823Enrollment3,443StartJan 2020Primary CompletionMar 2020CompletionApr 2020 - ObservationalCompleted
Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers
TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen
Healthy
NCT06261580Enrollment181StartJul 2021Primary CompletionOct 2021CompletionOct 2021 - ObservationalCompleted
An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge
TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen
Surgery
NCT06352125Enrollment338StartDec 2021Primary CompletionJan 2023CompletionJan 2023
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1 | Completed | SOLX (Investigational), AS-3 (Control) | NCT02145507 |
| Observational | Completed | - | NCT01357928 |
| Observational | Terminated | - | NCT01428102 |
| Observational | Completed | OrthoPat Advance | NCT01756976 |
| Observational | Completed | - | NCT01764061 |
| Observational | Completed | - | NCT02110576 |
| Not applicable | Completed | POLFA (Needle Assembly), Kawasumi (Needle Assembly) | NCT02476851 |
| Observational | Completed | TEG6s DOAC Cartridge | NCT02798328 |
| Not applicable | Completed | Updated Plasma Collection Feature, Current Plasma Collection Approach | NCT04320823 |
| Observational | Completed | TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen | NCT06261580 |
| Observational | Completed | TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen | NCT06352125 |